PhytoHealth Corporation announced company's current R&D progress on PG2, anti-osteoporosis, and moderateto severe pain relief new drugs. New drug under development #1: PG2 Lyophilized Injection(A) Phytohealth's ¡¨Botanical New Drug API Plant¡¨ has been granted the PIC/S GMP certificate by the TFDA of the Ministry of Health and Welfare in September, 2016. The plant is manufacturing PG2's API to fully supply the market need of major hospitals in Taiwan.(B) PG2 Lyophilized Injection 500mg, which is prescribed for un-recoverable moderate to severe cancer-related fatigue, has received NDA approval from TFDA for market sale. (C) Phase IV clinical trial for treating cancer-related fatigue: (a) Trial Title: PG2 Treatment for Improving Fatigue among Advanced Cancer Patients under Standard Palliative Care.(b) Institution: Nine medical centers, including MMH, SHH, CGMH-KL,TSGH, CCH, CMH-LY,CMUH, CGMH-LK, and CGMH-KS.(c) Trial Update: The clinical study report has been approved by TFDA.Nine manuscripts based on the clinical study results havebeen accepted for publication in the renowned medical associations and journals.(D) Clinical trial for treating ischemic stroke:(a) Trial Title: PG2 Injection 500mg for Acute Stroke Study(b) Institution: Fifteen medical centers, including NTUH and CMUH.(c) Trial Update: The study is one of industry-academia collaboration outcomes by CMUH's ¡¨Stroke Clinical Trials and Research Center of Excellence¡¨ through¡¨Industry-Academia Link Innovative Research Office¡¨. The clinical study report has been completed. Currently, the development is planning on subacute ischemic stroke treatment and the draft protocol has been completed. Contract research organizations (CROs) are approached for planning study budgets and timelines. (E) Clinical trial for treating hemorrhagic stroke (a) Trial Title: PG2 Injection 500mg for Spontaneous Intracerebral Hemorrhage Pilot Study. (b) Institution: China Medical University Hospital (c) Trial Update: The study is one of outcomes resulted from the co-established ¡¨Industry-Academia Link Innovative Research Office¡¨ with CMU. The results of the clinical trial have been published in a Nature-Series international journal- Scientific Reports. (F) Basic research-related to immune modulating effects of PG2: Two papers were published on International Journal of Medical Sciences and Nutrients earlier this year.(4) New drug in development #2: Anti-oteoporosis Clinical trial for preventing osteoporosis:(a) Trial Title: PH3 for the Prevention of Osteoporosis in Post-menopausal Women in Phase II, Double-Blind, Randomized, and Placebo Controlled Study (b) Institution: TVGH, CGMH, NTUH and MMH(c) Trial Update: Phase II clinical study was completed. The company continues to assess the compatibility of clinical trial regulations between Taiwan and China and to explore clinical trial cooperation possbility in accordance with clinical trials harmonization. (d) Filed IND annual report to US-FDA on 2020/04/08.(e) The manufacturing process of PH3 is continuously being optimizedto fulfill the CMC requirement for larger scale production of PH3. The specifications of PH3 drug product would be maintained to ensure batch to batch consistency and product quality.